Summary
• Applied Therapeutics, Inc. (APLT) fell 26.1% in after-hours trading to $0.1603 following an acquisition announcement by Cycle Pharmaceuticals.
• Cycle Pharmaceuticals aims to acquire APLT, targeting its lead drug candidate, govorestat, for central nervous system diseases.
• Despite a “Buy” rating from analysts, APLT’s stock has dropped 83% over the past year and shows weak momentum indicators.
Applied Therapeutics, Inc. (NASDAQ: APLT) saw a significant decline of 26.1% in after-hours trading, dropping to a price of $0.1603 from the last close of $0.2169. This movement occurred shortly after an acquisition announcement by Cycle Pharmaceuticals.
Acquisition Announcement Sparks Reaction
Today, Cycle Pharmaceuticals announced its intent to acquire Applied Therapeutics, focusing on the company’s lead drug candidate, govorestat. Described as a novel central nervous system penetrant Aldose Reductase Inhibitor, govorestat is designed for the treatment of central nervous system rare metabolic diseases. Despite the potential strategic upside from this acquisition, the market reacted negatively, indicating underlying concerns among investors.
Market Performance Overview
Recently, Applied Therapeutics has seen tumultuous performance metrics. The stock has dropped approximately 83% over the past year, with a quarterly performance decline of over 48%. Currently, the 14-day Relative Strength Index (RSI) stands at 30.7, signaling that the stock is approaching oversold territory. The trading volume today has reached approximately 1.84 million shares, which is notably lower than the average volume over the last three months of about 13 million.
Technical Indicators
Despite the short-term volatility, the longer-term trends suggest weakening momentum for Applied Therapeutics. The stock is currently below its 20-day simple moving average (SMA) by 12.3%, the 50-day SMA by 71.8%, and the 200-day SMA by 58.8%. This prolonged underperformance may signal difficulty attracting investor confidence, especially amidst news of the acquisition.
Analyst Sentiment
Currently, analysts maintain a “Buy” rating for APLT, although recent downgrades have occurred. Just last week, Leerink Partners adjusted its rating from “Outperform” to “Market Perform” while maintaining a price target range of $1-$2. This adjustment reflects a cautious approach as the market assesses the implications of the acquisition news along with company fundamentals.
Closing Summary
The stock’s substantial decline in after-hours trading highlights the market’s mixed reception of the acquisition announcement. As the situation unfolds, traders will be attentive to how performance metrics evolve and how investor sentiment may shift in the upcoming sessions.